ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0024

Detection of Synovial Signatures in Peripheral Blood of Patients with Rheumatoid Arthritis via a Novel Blood-Based DNA Capture Assay

Peter C. Taylor1, Jenya Antonova2, Jennifer Geis3, Katharine Dilger3, David Chernoff4, Diana Abdueva3, Nancy Shadick5 and Michael Weinblatt6, 1Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 2Compass Strategy and Research, Inc., San Francisco, CA, 3Aqtual Inc., Hayward, CA, 4Chernoff Consulting, Sausalito, CA, 5Brigham and Women's Hospital, Boston, MA, 6Harvard Medical School, Waban, MA

Meeting: ACR Convergence 2023

Keywords: Bioinformatics, Biomarkers, Fibroblasts, Synovial, Genomics and Proteomics, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0013–0039.5) Genetics, Genomics & Proteomics Poster

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: In rheumatoid arthritis [RA], synovial biopsies were shown to guide therapy selection1. However, biopsies require special training for clinicians and are semi-invasive for patients. Blood-based tests are a common procedure in clinical practice. Prior research failed to capture synovial signals in RA patients via blood because of the limited circulation of synovial-specific biomarkers and the dilution of molecular signals within the bloodstream. The study aims to investigate synovium-specific transcriptomic signal in blood plasma by employing a novel DNA capture platform to comprehensively analyze and characterize the molecular signatures in RA.

Methods: Plasma samples (n=229) from 89 individuals meeting 2010 ACR/EULAR classification criteria for RA, 62 with inflammatory conditions, 12 with OA, and 29 healthy controls (Table 1) were processed using a blood-based assay that enriches for non-hematopoietic signals. The epigenome atlas, comprised of 600,000 features, was evaluated using bootstrap methods to select features that robustly differentiate RA from non-RA samples to generate a candidate list of genomic feature locations. These were mapped to genes and compared to the reported pathways2 identified in whole blood and synovial tissue of patients with RA. A machine-learning training used 5-repeat 10-fold cross validation of the candidate features that have overlapping genes with synovial pathways. The training generated the average area under the curve (AUC) and performance metrics (sensitivity and specificity; Table 2)

Results: Participants had a mean (standard deviation, SD) age of 53.6 (16.63) years and were mostly female (67.9%) and white (63.3%; Table 2). The RA patients were mostly seropositive (70%) and biologic-naïve (93%). In the list of identified genomic features, 88% overlapped with synovium pathway genes and 30% with blood pathway genes. Within identified synovial signatures, 42% represent synovial fibroblast genes (Table 3); the remaining 58% of the features showed significant enrichment of immune cell types, including, CD4+ and CD8+ T-cells, B-cells, and macrophages.

Conclusion: The developed non-invasive DNA capture assay identified synovium-specific gene expression signatures in blood plasma of RA patients. Further clinical research is needed to validate these synovial signatures and confirm the clinical utility of the developed classification system.

1. Humby F, et al. (2019); PMID: 30878974
2. Rychkov D, et al. (2021); PMID: 34177888

Note: both Dr. Shadick and Dr. Weinblatt are last authors.

Supporting image 1

Table 1. Patient demographic characteristics

Supporting image 2

Table 2. Methodological definitions

Supporting image 3

Table 3. Synovial fibroblast genes identified within synovial signatures


Disclosures: P. Taylor: AbbVie, 2, Biogen, 2, Eli Lilly, 2, Fresenius, 2, Galapagos, 2, 5, Gilead Sciences, 2, GSK, 2, Janssen, 2, Nordic Pharma, 2, Pfizer Inc, 2, Sanofi, 2, UCB, 2; J. Antonova: Aqtual, Inc., 2; J. Geis: Aqtual, Inc., 3, 11; K. Dilger: AQTUAL, 3, 10, 11; D. Chernoff: Aqtual, Inc., 2, Reflexion Pharma, 2, 11, SetPoint Medical, 3, 11; D. Abdueva: Aqtual, Inc., 3, 4, 8, 10, 11; N. Shadick: Abbvie, 5, AQtual, 5, Bristol-Myers Squibb(BMS), 5, Janssen, 5; M. Weinblatt: Abbvie, 2, 5, Aclaris, 2, Amgen, 2, Aqtual, 5, Bristol Myers Squibb, 2, 5, Canfite, 11, Corevitas, 2, CorEvitas, 2, Eli Lilly, 2, Gilead, 2, 2, Glaxo Smith Kline, 2, Horizon, 2, Inmedix, 11, Janssen, 5, Johnson and Johnson, 2, Pfizer, 2, Prometheus Laboratories, 2, Rani, 2, Revolo, 2, Sanofi, 2, Sci Rhom, 2, Scipher, 2, 11, Set Point, 2, UCB, 2.

To cite this abstract in AMA style:

Taylor P, Antonova J, Geis J, Dilger K, Chernoff D, Abdueva D, Shadick N, Weinblatt M. Detection of Synovial Signatures in Peripheral Blood of Patients with Rheumatoid Arthritis via a Novel Blood-Based DNA Capture Assay [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/detection-of-synovial-signatures-in-peripheral-blood-of-patients-with-rheumatoid-arthritis-via-a-novel-blood-based-dna-capture-assay/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/detection-of-synovial-signatures-in-peripheral-blood-of-patients-with-rheumatoid-arthritis-via-a-novel-blood-based-dna-capture-assay/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology